HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

AbstractBACKGROUND:
Pirfenidone, an oral anti-inflammatory, antifibrotic agent with activity in idiopathic pulmonary fibrosis, may mediate anti-tumor activity in neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN) by inhibition of fibroblast proliferation and collagen synthesis. The primary objective of this open label, single arm phase II trial was to evaluate the activity of pirfenidone in children and young adults with inoperable PN.
PROCEDURE:
Patients (3-21 years) with NF1-related progressive PN received pirfenidone at the previously determined optimal dose (500 mg/m(2) orally, q8h) on a continuous dosing schedule (one cycle = 28 days). Volumetric MRI analysis was used to assess response. Progression was defined as ≥ 20% PN volume increase compared to baseline. Pirfenidone would be considered active if it doubled the median time to progression (TTP) compared to the TTP on the placebo arm of a phase II trial with the farnesyltransferase inhibitor tipifarnib, which used near identical eligibility criteria. Toxicities, objective response rate, and quality of life (QOL) also were evaluated.
RESULTS:
Thirty-six patients were enrolled and tolerated pirfenidone well with intermittent nausea and vomiting as the most frequent toxicities. A dose reduction was required in only three patients. The median TTP for pirfenidone was 13.2 months compared to 10.6 months for the placebo control group from the tipifarnib trial (two-tailed P = 0.92; one-tailed P = 0.46). No objective responses were observed.
CONCLUSIONS:
Pirfenidone was well tolerated, but did not demonstrate activity as defined in this trial and does not warrant further evaluation in children with NF1 and progressive PN.
AuthorsBrigitte C Widemann, Dusica Babovic-Vuksanovic, Eva Dombi, Pamela L Wolters, Stewart Goldman, Staci Martin, Anne Goodwin, Wendy Goodspeed, Mark W Kieran, Bruce Cohen, Susan M Blaney, Allison King, Jeffrey Solomon, Nicholas Patronas, Frank M Balis, Elizabeth Fox, Seth M Steinberg, Roger J Packer
JournalPediatric blood & cancer (Pediatr Blood Cancer) Vol. 61 Issue 9 Pg. 1598-602 (Sep 2014) ISSN: 1545-5017 [Electronic] United States
PMID24753394 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, N.I.H., Intramural, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
Copyright© 2014 Wiley Periodicals, Inc.
Chemical References
  • Antineoplastic Agents
  • Pyridones
  • Tumor Necrosis Factor-alpha
  • pirfenidone
Topics
  • Adolescent
  • Adult
  • Antineoplastic Agents (therapeutic use)
  • Child
  • Child, Preschool
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Neoplasm Staging
  • Neurofibroma, Plexiform (drug therapy, mortality, pathology)
  • Neurofibromatosis 1 (drug therapy, mortality, pathology)
  • Prognosis
  • Pyridones (therapeutic use)
  • Quality of Life
  • Survival Rate
  • Time Factors
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: